{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:22Z","timestamp":1794360502840,"version":"4.9.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,10,2]]},"DOI":"10.1080\/14740338.2024.2394578","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T10:43:52Z","timestamp":1723891432000},"page":"1237-1247","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review"],"prefix":"10.1080","volume":"23","author":[{"given":"Eszter","family":"Czifrus","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-952X","authenticated-orcid":false,"given":"Daniel J.","family":"Berlau","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Regis University, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.23528"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_3_4_5_1","unstructured":"Duchenne muscular dystrophy \u2013 symptoms causes treatment. NORD; [cited 2024 Mar 30]. Available from: https:\/\/rarediseases.org\/rare-diseases\/duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-005-2584-x"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/JNNP.2007.141721"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10654-020-00613-8"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES201018168"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/GENES11080837"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES9101447"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30026-7"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2021.689533"},{"key":"e_1_3_4_16_1","volume-title":"Exondys 51 [Prescribing information]","year":"2016","unstructured":"Exondys 51 [Prescribing information]. Cambridge (MA): Sarepta Therapeutics, Inc.; 2016."},{"key":"e_1_3_4_17_1","volume-title":"Amondys 45 [Prescribing information]","year":"2021","unstructured":"Amondys 45 [Prescribing information]. Cambridge (MA): Sarepta Therapeutics, Inc.; 2021."},{"key":"e_1_3_4_18_1","volume-title":"Vyondys 53 [Prescribing information]","year":"2019","unstructured":"Vyondys 53 [Prescribing information]. Cambridge (MA): Sarepta Therapeutics, Inc.; 2019."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01339-3"},{"key":"e_1_3_4_20_1","volume-title":"Viltepso [Prescribing information]","year":"2020","unstructured":"Viltepso [Prescribing information]. Paramus (NJ): NS Pharma, Inc.; 2020."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/NAT.2020.0845"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210682"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.26755"},{"key":"e_1_3_4_24_1","unstructured":"Study Details. A randomized double-blind placebo-controlled study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne muscular dystrophy (DMD). ClinicalTrials.gov. [cited 2024 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03769116#publications"},{"key":"e_1_3_4_25_1","unstructured":"FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy. FDA; [cited 2024 Mar 30]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy"},{"key":"e_1_3_4_26_1","unstructured":"FDA OKs givinostat for Duchenne muscular dystrophy. [cited 2024 Mar 29]. Available from: https:\/\/www.medscape.com\/viewarticle\/fda-oks-givinostat-duchenne-muscular-dystrophy-2024a10005fv?src=&ecd=wnl_newsalrt_240322_MSCPEDIT_FDA_Duchenne_etid6392622&uac=7087EX&impID=6392622"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00036-X"},{"key":"e_1_3_4_28_1","unstructured":"Study Details. Givinostat in Duchenne\u2019s muscular dystrophy long-term safety and tolerability study. ClinicalTrials.gov. [cited 2024 Mar 29]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03373968?cond=givinostat&rank=2"},{"key":"e_1_3_4_29_1","unstructured":"Duchenne and Becker muscular dystrophy: glucocorticoid and disease-modifying treatment - UpToDate. [cited 2024 Mar 30]. Available from: https:\/\/www.uptodate.com\/contents\/duchenne-and-becker-muscular-dystrophy-glucocorticoid-and-disease-modifying-treatment?sectionName=GLUCOCORTICOID%20TREATMENT&topicRef=6181&anchor=H997077185&source=see_link#H997077185"},{"key":"e_1_3_4_30_1","unstructured":"Agamree [Prescribing information]. Coral Gables (FL): Catalyst Pharmaceuticals Inc.; 2023 [cited 2024 Mar 9]. Available from: www.fda.gov\/med\/watch"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373947-6.00252-X"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TEM.2017.10.010"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-14-0471"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PPEDCARD.2022.101557"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40360-016-0111-8"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/HMG\/DDAD173"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.26508\/LSA.201800186"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00011-016-0956-8"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/EMMM.201302621"},{"key":"e_1_3_4_42_1","volume-title":"Rayos [Prescribing information]","year":"1955","unstructured":"Rayos [Prescribing information]. Deerfield (IL): Horizon Pharma USA, Inc.; 1955. Available from: www.fda.gov\/me\/dwatch"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00003"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016287104656"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197904020-00004"},{"key":"e_1_3_4_46_1","volume-title":"Emflaza [Prescribing information]","year":"2017","unstructured":"Emflaza [Prescribing information]. South Plainfield (NJ): PTC Therapeutics, Inc.; 2017. Available from: www.fda.gov\/medwat\/ch"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108776936.043"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.2217\/CER-2022-0055"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.PUB4"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINTHERA.2017.09.011"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.26191"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2022.4315"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/CER-2021-0018"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.57264\/CER-2022-0190"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2480"},{"key":"e_1_3_4_57_1","unstructured":"FDA approves vamorolone for treatment of Duchenne muscular dystrophy in patients aged 2 years and older. [cited 2024 Feb 25]. Available from: https:\/\/www.pharmacytimes.com\/view\/fda-approves-vamorolone-for-treatment-of-duchenne-muscular-dystrophy-in-patients-aged-2-years-and-older"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.STEROIDS.2018.02.010"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2018.09.007"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCPH.1632"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1003222"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2021.44178"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2022.2480"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221575"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/JNNP-2012-303902"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.NMD.2006.01.010"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.043"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/PPUL.23172"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/LIFE11080752"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16267"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210776"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.23793"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/ARCHDISCHILD-2015-308654"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/AJMG.1320290223"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2394578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:01:04Z","timestamp":1728601264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2394578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,2]]}},"alternative-id":["10.1080\/14740338.2024.2394578"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2394578","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}